A simplified method at lowest cost for autologous, non-cryopreserved, unmanipulated, periphral hematopoetic stem cells transplant in multiple myeloma and non-Hodgkin's lymphoma: Asian scenario.

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

“…Several studies and one meta-analysis have shown that noncryopreserved autologous HSCT for MM is simple, safe and cost-effective and gives results that are at least equivalent to autologous HSCT with cryopreservation [79][80][81][82][83][84]. TRM at day 100 post-HSCT has ranged between 0.0 and 3.4% [80,[82][83][84]. Noncryopreserved stem cells can be infused till day 5 postapheresis without viability loss provided they are stored at +4°C in conventional blood bank refrigerator [79,81,82,84].…”

“…HSCT without cryopreservation has several advantages including (1) simplicity of implementation, (2) allowing autologous HSCT to be performed entirely as outpatient, 3 (2) limitation of the use of standard HD chemotherapy schedules such as BEAM (BCNU, etoposide, cytarabine and melphalan) employed in the autologous HSCT for lymphoma and (3) inability to store part of the collection and reserving it for a second autologous HSCT in case a rich product is obtained [79][80][81][82][83][84].…”

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Agents and Targeted Therapies

“…Several studies and 1 meta-analysis have shown that: noncryopreserved autologous HSCT for MM is simple, safe and costeffective and gives results that are equivalent to auto-HSCT with cryopreservation [33][34][35][36][37][38]. TRM at day 100 post-HSCT has ranged between 0.0% and 3.4 % [34,[36][37][38].…”

“…Several studies and 1 meta-analysis have shown that: noncryopreserved autologous HSCT for MM is simple, safe and costeffective and gives results that are equivalent to auto-HSCT with cryopreservation [33][34][35][36][37][38]. TRM at day 100 post-HSCT has ranged between 0.0% and 3.4 % [34,[36][37][38]. Non-cryopreserved stem cells can be infused till day 5 post-apheresis without viability loss provided they are stored at + 4 o C in conventional blood bank refrigerator [33,35,36,38].…”

“…(1) simplicity of implementation, (2) allowing autologous HSCT to be performed entirely as outpatient, (3) reduction of transplantation costs, (4) reducing the time between the last induction therapy and high-dose chemotherapy, (5) prevention of DMSO toxicity, (6) expansion of the number of medical institutions performing stem cell therapies, (7) no significant loss of viability of the collected HSCs provided stem cell infusion is made within 5 days of apheresis, and (8) potent engraftment syndrome and autologous graft versus host disease (GVHD) [33][34][35][36][37][38]. HSCT without cryopreservation has the following disadvantages: (1) limitation of the use of standard high dose schedules such as BEAM (BCNU, etoposide, cytarabine and melphalan) employed in autologous HSCT for lymphoma, (2) plenty of coordination needed between various teams regarding timing of: stem cell mobilization, apheresis, administration of conditioning therapy, and infusion of stem cells, and (3) inability to store part of the collection and reserving it for a second autologous HSCT in case a rich product is obtained [33][34][35][36][37][38] Outpatient HSCT MM is the leading indication for autologous HSCT worldwide. Patients with MM are ideal candidates for outpatient autologous HSCT because of the following reasons: the ease of administering high-dose melphalan, the relatively low extra-hematological toxicity and the short period of neutropenia [39].…”